THIS IS A PUBLIC ANNOUNCEMENT FOR INFORMATION PURPOSES ONLY AND IS NOT A PROSPECTUS ANNOUNCEMENT AND DOES NOT CONSTITUTE AN INVITATION OR OFFER TO ACQUIRE, PURCHASE OR SUBSCRIBE TO SECURITIES.
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION DIRECTLY OR INDIRECTLY OUTSIDE INDIA.

INITIAL PUBLIC OFFERING OF EQUITY SHARES ON THE MAIN BOARD OF THE BSE LIMITED (**"BSE"**) AND "NATIONAL STOCK EXCHANGE OF INDIA LIMITED (**"NSE"**, AND TOGETHER WITH BSE, THE **"STOCK EXCHANGES"**) IN COMPLIANCE WITH CHAPTER II OF THE SECURITIES AND EXCHANGE BOARD OF INDIA (ISSUE OF CAPITAL AND DISCLOSURE REQUIREMENTS) REGULATIONS, 2018, AS AMENDED (**"SEBI ICDR REGULATIONS"**).

SYMBIOTEC

SYMBIOTEC PHARMALAB LIMITED

(TO BE LISTED ON THE MAIN BOARD OF BSE AND NSE)

(Please scan this QR Code to view the Red Herring Prospectus and Abridged Prospectus)

Our Company was incorporated as 'Symbiotec Pharmalab Private Limited' as a private limited company under the Companies Act, 1956, pursuant to a certificate of incorporation dated September 20, 2002, issued by the Registrar of Companies, Madhya Pradesh and Chhattisgarh. Subsequently, in the interest of business expansion and issuing fresh shares to the public to meet requirements of funds for a project being undertaken by the Company which would have resulted into increase in the members of the Company beyond fifty, our Company was converted from a private limited company to a public limited company, pursuant to the Board resolution dated September 22, 2005 and a resolution passed in the extraordinary general meeting of our Shareholders held on October 18, 2005 and the name of our Company was changed to Symbiotec Pharmalab Limited, and a certificate of change of name dated October 27, 2005 was issued to our Company by the Registrar of Companies, Madhya Pradesh & Chhattisgarh. Further, considering the absence of public involvement in the shareholding pattern and the management of the Company, our Company was converted to a private limited company pursuant to the Board resolution dated April 23, 2014 and a resolution passed in the extraordinary general meeting of our Shareholders on May 22, 2014 and the name of our Company was changed to Symbiotec Pharmalab Private Limited and a certificate of incorporation, consequent upon conversion to a private limited was issued by the RoC on July 25, 2014. Thereafter, as part of the Company's strategic vision for future growth and expansion, our Company was converted into a public company, pursuant to the Board resolution dated September 11, 2025 and a special resolution dated September 12, 2025 passed in the extraordinary general meeting of our Shareholders. Consequently the name of our Company was changed to Symbiotec Pharmalab Limited and a fresh certificate of incorporation dated September 26, 2025, consequent upon conversion to a public company, was issued by the Registrar of Companies, Central Processing Centre. For further details on the changes in the name and registered office of our Company, see "*History and Certain Corporate Matters*" on page 265 of the Red Herring Prospectus dated August 18, 2026 ("**RHP**").

Corporate Identity Number: U24232MP2002PLC015293; **Website:** www.symbiotec.com
Registered and Corporate Office: 385/2, Pigdamber, Rau, Mhow, Indore – 453 331, Madhya Pradesh, India
Contact Person: Salil Jain, Company Secretary and Compliance Officer; **Telephone:** +91 731 667 6405; **Email:** secretarial@symbiotec.com

THE PROMOTERS OF OUR COMPANY: ANIL SATWANI, KASHISH SATWANI, SUSHIL SATWANI AND SATWANI HOLDINGS LLP

INITIAL PUBLIC OFFERING OF UP TO [●] EQUITY SHARES OF FACE VALUE OF ₹2 EACH ("EQUITY SHARES") OF OUR COMPANY FOR CASH AT A PRICE OF ₹[●] PER EQUITY SHARE (INCLUDING A SHARE PREMIUM OF ₹[●] PER EQUITY SHARE) ("OFFER PRICE") AGGREGATING UP TO ₹17,570.00 MILLION ("OFFER"). THE OFFER COMPRISES A FRESH ISSUE OF UP TO [●] EQUITY SHARES OF FACE VALUE OF ₹2 EACH AGGREGATING UP TO ₹1,500.00 MILLION BY OUR COMPANY ("FRESH ISSUE") AND AN OFFER FOR SALE OF UP TO [●] EQUITY SHARES OF FACE VALUE OF ₹2 EACH ("OFFERED SHARES") AGGREGATING UP TO ₹16,070.00 MILLION, COMPRISING OF UP TO [●] EQUITY SHARES OF FACE VALUE OF ₹2 EACH AGGREGATING UP TO ₹1,440.00 MILLION BY SATWANI HOLDINGS LLP (THE "PROMOTER SELLING SHAREHOLDER"), UP TO [●] EQUITY SHARES OF FACE VALUE OF ₹2 EACH AGGREGATING UP TO ₹9,880.00 MILLION BY ROSEWOOD INVESTMENTS AND UP TO [●] EQUITY SHARES OF FACE VALUE OF ₹2 EACH AGGREGATING UP TO ₹4,750.00 MILLION BY INDIA BUSINESS EXCELLENCE FUND – III (THE "INVESTOR SELLING SHAREHOLDERS", AND TOGETHER WITH THE PROMOTER SELLING SHAREHOLDER, THE "SELLING SHAREHOLDERS" AND SUCH OFFER FOR SALE OF EQUITY SHARES BY THE SELLING SHAREHOLDERS, THE "OFFER FOR SALE"). THE OFFER WILL CONSTITUTE [●]% OF THE POST-OFFER PAID UP EQUITY SHARE CAPITAL OF OUR COMPANY.

THE OFFER INCLUDES A RESERVATION OF [●] EQUITY SHARES OF FACE VALUE OF ₹2 EACH AGGREGATING ₹30.00 MILLION (CONSTITUTING UP TO [●]% OF THE POST OFFER PAID-UP EQUITY SHARE CAPITAL OF OUR COMPANY), FOR SUBSCRIPTION BY ELIGIBLE EMPLOYEES (THE "EMPLOYEE RESERVATION PORTION"). THE OFFER LESS THE EMPLOYEE RESERVATION PORTION IS HEREINAFTER REFERRED TO AS THE "NET OFFER". THE OFFER AND THE NET OFFER SHALL CONSTITUTE [●]% AND [●]%, RESPECTIVELY, OF THE POST-OFFER PAID-UP EQUITY SHARE CAPITAL OF OUR COMPANY. OUR COMPANY, IN CONSULTATION WITH THE BOOK RUNNING LEAD MANAGERS, MAY OFFER A DISCOUNT OF UP TO [●]% (EQUIVALENT TO ₹[●] PER EQUITY SHARE) TO THE OFFER PRICE TO ELIGIBLE EMPLOYEES BIDDING UNDER THE EMPLOYEE RESERVATION PORTION ("EMPLOYEE DISCOUNT").

THE FACE VALUE OF THE EQUITY SHARE IS ₹2 EACH. THE OFFER PRICE IS [●] TIMES THE FACE VALUE OF THE EQUITY SHARES. THE PRICE BAND, THE MINIMUM BID LOT AND THE EMPLOYEE DISCOUNT WILL BE DECIDED BY OUR COMPANY, IN CONSULTATION WITH THE BOOK RUNNING LEAD MANAGERS AND WILL BE ADVERTISED IN ALL EDITIONS OF FINANCIAL EXPRESS, A WIDELY CIRCULATED ENGLISH NATIONAL DAILY NEWSPAPER, IN ALL EDITIONS OF JANSATTA, A WIDELY CIRCULATED HINDI NATIONAL DAILY NEWSPAPER AND INDORE EDITION OF INDORE SAMACHAR, A HINDI DAILY NEWSPAPER (HINDI ALSO BEING THE REGIONAL LANGUAGE OF MADHYA PRADESH, WHERE OUR COMPANY'S REGISTERED AND CORPORATE OFFICE IS LOCATED), AT LEAST TWO WORKING DAYS PRIOR TO THE BID / OFFER OPENING DATE AND SHALL BE MADE AVAILABLE TO BSE LIMITED AND NATIONAL STOCK EXCHANGE OF INDIA LIMITED FOR UPLOADING ON THEIR RESPECTIVE WEBSITES IN ACCORDANCE WITH THE SEBI ICDR REGULATIONS.

NOTICE TO INVESTORS AND ADDENDUM TO THE RED HERRING PROSPECTUS AND ABRIDGED PROSPECTUS EACH DATED AUGUST 18, 2026 ("ADDENDUM")

This Addendum is in relation to the Red Herring Prospectus ("**RHP** or "**Red Herring Prospectus**") and the Abridged Prospectus ("**Abridged Prospectus**") each dated August 18, 2026, filed by the Company with the Registrar of Companies, Madhya Pradesh at Gwalior ("**RoC**") and submitted thereafter with SEBI and the Stock Exchanges, in connection with the Offer. Potential Bidders may note the following:

1) Our Investor Selling Shareholders, Rosewood Investments and India Business Excellence Fund – III have, pursuant to separate share purchase agreements each dated August 19, 2026, entered with the transferees set out in the table below, transferred an aggregate of 6,557,619 Equity Shares of face value of ₹2 each, representing 10.43% of the pre-Offer paid up Equity Share capital of our Company, on a fully-diluted basis ("**Sale Share**s") at a price of ₹988.00 per Equity Share, as follows:

S. No.	Nature of Transaction	Name of Transferor	Name of the Transferee	Date of Transfer	Whether transferee is connected, in any manner, with the Company, the Promoters, members of the Promoter Group (including the Promoter Selling Shareholders), the Directors, the Key Managerial Personnel, the Subsidiaries, and group companies and their respective directors and key managerial personnel*	Number of Equity Shares of face value of ₹2 each transferred	Percentage of pre-Offer share capital of the Company on a fully diluted basis, after the transfer of Sale Shares (%)	Transfer Price per Sale Share (₹)	Total consideration (in ₹ million)
1.	Secondary Sale	Rosewood Investments	Think India Opportunities Master Fund LP	August 19, 2026	No	1,771,255	2.82	988.00	1,750.00
2.	Secondary Sale	Rosewood Investments	Dymon Asia Multi-Strategy Investment (Singapore) Pte. Limited	August 19, 2026	No	1,012,145	1.61	988.00	1,000.00
Sub-total (A)						**2,783,400**	**4.43**	**-**	**2,750.00**
1.	Secondary Sale	India Business Excellence Fund – III	ValueQuest Founders Conviction LVF	August 19, 2026	No	1,771,255	2.82	988.00	1,750.00
2.	Secondary Sale	India Business Excellence Fund – III	ValueQuest Fastercap Fund II	August 19, 2026	No	253,035	0.40	988.00	250.00
3.	Secondary Sale	India Business Excellence Fund – III	WhiteOak Capital India Opportunities Fund	August 19, 2026	No	506,071	0.81	988.00	500.00
4.	Secondary Sale	India Business Excellence Fund – III	WhiteOak Capital Equity Fund	August 19, 2026	No	50,607	0.08	988.00	50.00
5.	Secondary Sale	India Business Excellence Fund – III	WhiteOak Capital Healthcare Opportunities Fund	August 19, 2026	No	50,607	0.08	988.00	50.00
6.	Secondary Sale	India Business Excellence Fund – III	Singularity Equity Fund I	August 19, 2026	No	454,395	0.72	988.00	448.94
7.	Secondary Sale	India Business Excellence Fund – III	Waterfield Flagship Fund II	August 19, 2026	No	151,820	0.24	988.00	150.00
8.	Secondary Sale	India Business Excellence Fund – III	Eterna Prima - Scheme II	August 19, 2026	No	101,215	0.16	988.00	100.00
9.	Secondary Sale	India Business Excellence Fund – III	1729 Growth Fund I	August 19, 2026	No	101,215	0.16	988.00	100.00
10.	Secondary Sale	India Business Excellence Fund – III	Jaya Chandrakant Gogri	August 19, 2026	No	101,215	0.16	988.00	100.00
11.	Secondary Sale	India Business Excellence Fund – III	Anshul Goel	August 19, 2026	No	50,605	0.08	988.00	50.00
12.	Secondary Sale	India Business Excellence Fund – III	Piyush Jalan Family Trust	August 19, 2026	No	50,605	0.08	988.00	50.00
13.	Secondary Sale	India Business Excellence Fund – III	Arvind Kapur	August 19, 2026	No	50,605	0.08	988.00	50.00
14.	Secondary Sale	India Business Excellence Fund – III	Landmark Capital Markets Private Limited	August 19, 2026	No	50,605	0.08	988.00	50.00
15.	Secondary Sale	India Business Excellence Fund – III	Aluka Kavitha	August 19, 2026	No	30,364	0.05	988.00	30.00
Sub-total (B)						**3,774,219**	**6.00**	**-**	**3,728.93**
Total (A+B)						**6,557,619**	**10.43**	**-**	**6,478.93**

**For the purpose of this confirmation, (i)'connected with' is deemed to mean that (a) there are no common directorships or common key managerial personnel between the Subject Persons and the investment manager of the transferees; and/or (b) there is no more than 1% equity investment interest by the transferees and investment manager of the transferees in the Subject Persons and also of the Subject Persons in the investment manager of the Purchasers and (ii) "Subject Persons" shall mean, collectively, the Company and its Promoters and members of the Promoter Group (including the Seller), Directors, Key Managerial Personnel and Subsidiaries of the Company and their respective directors and key managerial personnel.*

2) Please note that the Sale Shares do not form part of the Equity Shares proposed to be offered for sale by Rosewood Investments and India Business Excellence Fund – III in the Offer for Sale. Further, the Sale Shares shall be subject to lock-in in accordance with Regulation 17 of the SEBI ICDR Regulations, as applicable, in the hands of the transferee.

3) As a result of the transfer of the Sale Shares, the shareholding of Rosewood Investments in our Company has reduced from 21,825,492 Equity Shares, representing 34.78% of the pre-Offer paid-up Equity Share capital of our Company on a fully diluted basis as on the date of RHP and Abridged Prospectus to 19,042,092 Equity Shares, representing 30.34% of the pre-Offer paid-up Equity Share capital of our Company on a fully diluted basis. Further, the shareholding of India Business Excellence Fund – III has reduced from 15,160,906 Equity Shares, representing 24.16% of the pre-Offer paid-up Equity Share capital of our Company on a fully diluted basis as on the date of RHP and Abridged Prospectus to 11,386,687 Equity Shares, representing 18.14% of the pre-Offer paid-up Equity Share capital on a fully diluted basis of our Company. Accordingly, the disclosures in relation to the pre-Offer shareholding of Rosewood Investments and India Business Excellence Fund – III in the section "Capital Structure" beginning on page 106 of the RHP, as on the date of this Addendum, stands modified, to the extent applicable, as follows:

Name of the Selling Shareholder	Number of Equity Shares held on a fully diluted basis, prior to the transfer of Sale Shares	Percentage of share capital on a fully diluted basis, prior to the transfer of Sale Shares (%)	Number of Equity Shares held on a fully diluted basis, after the transfer of Sale Shares	Percentage of pre-Offer share capital of the Company on a fully diluted basis, after the transfer of Sale Shares (%)
Rosewood Investments	21,825,492	34.78	19,042,092	30.34
India Business Excellence Fund – III	15,160,906	24.16	11,386,687	18.14

Addendum to RHP and Abridged Prospectus

As a result of the transfer of Sale Shares, the disclosures in relation to Rosewood Investments and India Business Excellence Fund – III shall stand updated and be read in the following manner, across the RHP and Abridged Prospectus:

1. ***The disclosure in the section "Capital Structure - Weighted average cost of acquisition of all equity shares transacted in the one year, 18 months and three years preceding the date of the Red Herring Prospectus" on page 122 of the RHP.***

Period	Weighted average cost of acquisition per equity share (in ₹)^	Cap Price is 'x' times the weighted average cost of acquisition^	Range of acquisition price per equity share: lowest price – highest price (in ₹)^#
Last one year preceding the date of the Red Herring Prospectus	440.00	2.25	0-988
Last 18 months preceding the date of the Red Herring Prospectus	432.98	2.28	0-988
Last three years preceding the date of the Red Herring Prospectus	432.98	2.28	0-988

^As certified by M/s. A B M S & Associates, Chartered Accountants by way of their certificate dated August 19, 2026.

#Adjusted for sub-division of equity shares.

2. ***Pre-Offer shareholding as on the date of the Red Herring Prospectus and post-Offer shareholding as at Allotment of our Promoters, Promoter Group and additional top 10 Shareholders on page 123 of the Red Herring Prospectus.***

The aggregate pre-Offer shareholding as on the date of the Red Herring Prospectus and post-Offer shareholding as at Allotment of our Promoters, the members of our Promoter Group (other than our Promoters), additional top 10 Shareholders and other public shareholders, as a percentage of the pre-Offer and post-Offer paid-up Equity Share capital of our Company is set out below:

S. No.	Name of Shareholder	Pre-Offer shareholding		Post-Offer shareholding as at Allotment*#			
				At the lower end of the Price Band (₹938.00)		At the upper end of the Price Band (₹988.00)	
		Number of Equity Shares of face value of ₹2 each	% of total pre-Offer paid up Equity Share capital on a fully diluted basis$	Number of Equity Shares of face value of ₹2 held	% of the total post-Offer paid-up Equity Share capital on a fully diluted basis@	Number of Equity Shares of face value of ₹2 held	% of the total post-Offer paid-up Equity Share capital on a fully diluted basis@
Promoters							
1.	Anil Satwani	2,810,896	4.48	2,810,896	4.37	2,810,896	4.37
2.	Kashish Satwani	2,750,896	4.38	2,750,896	4.27	2,750,896	4.28
3.	Sushil Satwani	1,233,938	1.97	1,233,938	1.92	1,233,938	1.92
4.	Satwani Holdings LLP^	11,277,374	17.97	9,742,193	15.14	9,819,885	15.28
	Sub-total (A)	**18,073,104**	**28.80**	**16,537,923**	**25.70**	**16,615,615**	**25.85**
Promoter Group (other than our Promoters)							
5.	Kashish and Anil Satwani Family Trust	350,000	0.56	350,000	0.54	350,000	0.54
6.	Arjun Anil Satwani Family Trust	2,199,104	3.50	2,199,104	3.42	2,199,104	3.42
7.	Krishna Anil Satwani Family Trust	2,199,104	3.50	2,199,104	3.42	2,199,104	3.42
8.	Sunil Satwani	10,000	0.02	10,000	0.02	10,000	0.02
9.	Swati Sachdev	10,000	0.02	10,000	0.02	10,000	0.02
	Sub-total (B)	**4,768,208**	**7.60**	**4,768,208**	**7.41**	**4,768,208**	**7.42**
Additional top 10 Shareholders							
10.	Rosewood Investments	19,042,092	30.34	8,509,043	13.22	9,042,092	14.07
11.	India Business Excellence Fund – III	11,386,687	18.14	6,322,722	9.82	6,578,995	10.23
12.	Think India Opportunities Master Fund LP	1,771,255	2.82	1,771,255	2.75	1,771,255	2.76
13.	ValueQuest Founders Conviction LVF	1,771,255	2.82	1,771,255	2.75	1,771,255	2.76
14.	Dymon Asia Multi-Strategy Investment (Singapore) Pte. Limited	1,012,145	1.61	1,012,145	1.57	1,012,145	1.57
15.	Prakash Sawlani	575,553	0.92	575,553	0.89	575,553	0.90
16.	WhiteOak Capital India Opportunities Fund	506,071	0.81	506,071	0.79	506,071	0.79
17.	Motilal Oswal India Excellence Fund – Mid to Mega Series III	505,000	0.80	505,000	0.78	505,000	0.79
18.	Singularity Equity Fund I	454,395	0.72	454,395	0.71	454,395	0.71
19.	Mahendra Fulchand Sundesha	329,133	0.52	329,133	0.51	329,133	0.51
	Sub-total (C)	**3,73,53,586**	**59.52**	**2,17,56,572**	**33.80**	**22,545,894**	**35.07**
Other public shareholders							
20.	-**	2,539,953	4.05	21,274,689	33.05	20,326,395	31.62
	Sub-total (D)	2,539,953	4.05	21,274,689	33.05	20,326,395	31.62
	Total (A + B + C + D)	**62,734,851**	**100.00*****	**64,337,392**	**100.00*****	**64,256,112**	**100.00*****

^Also, a Promoter Selling Shareholder.

#To be updated in the Prospectus prior to filing with the RoC.

**Assuming full subscription in the Offer. The post-Offer shareholding details as at Allotment will be based on the actual subscription and the Offer Price and updated in the Prospectus, subject to finalization of the Basis of Allotment. Also, this table assumes there is no transfer of shares by the Shareholders between the date of the price band advertisement and Allotment, and if any such transfers occur prior to the date of Prospectus, it will be updated in the shareholding pattern in the Prospectus.*

$The percentage of the Equity Share capital on a fully diluted basis has been calculated assuming the exercise of all vested options as on the date under the ESOP Scheme.

@The percentage of the Equity Share capital on a fully diluted basis will be calculated assuming the exercise of all vested options under the ESOP Scheme as on the date of the Prospectus and considering any transfers of Equity Shares by existing shareholders after the date of the pre-issue and Price Band advertisement until date of Prospectus.

***As on the date of the Red Herring Prospectus, our Company has 101 public shareholders.*

****This includes 24,570 ESOP options that have been vested but not been exercised under ESOP Scheme.*

Continued on next page...

...continued from previous page.

3. ***Weighted average cost of acquisition at which Equity Shares were acquired by the Promoters (which includes the Promoter Selling Shareholder) and Selling Shareholders as on date of the Red Herring Prospectus and in the one year preceding the date of the Red Herring Prospectus on page 123 of the Red Herring Prospectus.***

Except as disclosed below, no Equity Shares have been acquired by the Promoters (which includes the Promoter Selling Shareholder) and Selling Shareholders as on date of the Red Herring Prospectus and in the one year preceding the date of the Red Herring Prospectus:

S. No.	Name of Promoter	Number of Equity Shares of face value of ₹ 2 each held as on date	WACA per Equity Share (in ₹)	Number of Equity Shares of face value of ₹ 2 each acquired in last one year	WACA of Equity Shares acquired in last one year
Promoters					
1.	Anil Satwani	2,810,896	276.00	3,120,000	276.00
2.	Kashish Satwani	2,750,896	273.04	27,00,000	276.00
3.	Sushil Satwani	1,233,938	72.37	313,938	276.00
4.	Satwani Holdings LLP^	11,277,374	49.43	2,227,734	217.58
Selling Shareholders					
1.	Rosewood Investments	19,042,092	147.21	NA	NA
2.	India Business Excellence Fund - III	11,386,687	147.21	NA	NA

As certified by M/s. A B M S & Associates, Chartered Accountants by way of their certificate dated August 19, 2026.

^Also participating as the Promoter Selling Shareholder.

4. ***Capital Structure on page 126 of the RHP***

As on date, Rosewood Investments currently hold 19,042,092 Equity Shares of face value of ₹2 each, equivalent of 30.34% of the issued, subscribed and paid-up equity share capital of our Company on fully diluted basis. However, Rosewood Investments' shareholding in our Company, upon completion of the Offer, would be less than 25.00% of the post-Offer issued and paid-up Equity Share capital of our Company.

5. ***The disclosure in the section "Capital Structure - Shareholding Pattern of our Company" on page 130 of the RHP, will be suitably updated in the Prospectus.***

6. ***Capital Structure on page 131 of the RHP***

As on date, our Company has 110 Shareholders.

7. ***Major shareholders on page 131 of the RHP***

The list of our major Shareholders' and the number of Equity Shares held by them is provided below:

a) The details of our Shareholders' holding 1% or more of the paid-up Equity Share capital of our Company on a fully diluted basis, as on the date are set forth below:

S. No.	Name of the Shareholder	Number of Equity Shares of face value of ₹2 each held	Percentage of the pre-Offer Equity Share capital on a fully diluted basis (%)*
1.	Anil Satwani	2,810,896	4.48
2.	Kashish Satwani	2,750,896	4.38
3.	Sushil Satwani	1,233,938	1.97
4.	Satwani Holdings LLP	11,277,374	17.97
5.	Arjun Anil Satwani Family Trust	2,199,104	3.50
6.	Krishna Anil Satwani Family Trust	2,199,104	3.50
7.	India Business Excellence Fund – III	11,386,687	18.14
8.	Rosewood Investments **	19,042,092	30.34
9.	Think India Opportunities Master Fund LP	1,771,255	2.82
10.	ValueQuest Founders Conviction LVF	1,771,255	2.82
11.	Dymon Asia Multi-Strategy Investment (Singapore) Pte. Limited	1,012,145	1.61
Total		**57,454,746**	**91.55**

**The percentage of the Equity Share capital on a fully diluted basis has been calculated assuming the exercise of all vested options as on date under the ESOP Scheme.*

***Rosewood Investments' shareholding in our Company, upon completion of the Offer, would be less than 25.00% of the post-Offer issued and paid-up Equity Share capital of our Company.*

8. ***As a result of the transfer of the Sale Shares, disclosures in the sections "Basis for Offer Price - Weighted average cost of acquisition ("WACA"), Floor Price and Cap Price – B) The price per share of our Company (as adjusted for corporate actions, including split and bonus issuances) based on the secondary sale / acquisition of shares (equity / convertible securities) (excluding gifts) involving any of the Promoters or members of the Promoter Group or Selling Shareholders or other Shareholders with the right to nominate directors on our Board during the 18 months preceding the date of filing of the Red Herring Prospectus, where the acquisition or sale is equal to or more than 5% of the fully diluted paid-up share capital of our Company (calculated based on the pre-Offer capital before such transaction/s and excluding employee stock options granted but not vested under the ESOP Scheme), in a single transaction or multiple transactions combined together over a span of rolling 30 days ("Secondary Transactions")" on page 160 of the RHP, stands modified as below:***

Date of transfer	Number of Equity Shares transacted	Percentage of paid-up Equity Share capital on fully diluted basis (%)	Face value of Equity Shares	Price per Equity Share	Nature of Consideration	Nature of transaction	Details of Transfer		
							From	To	No. of Shares
August 17, 2026	17,12,344	2.73%	2	200	Cash	Transfer	India Business Excellence Fund- III	Satwani Holdings LLP	197,244
							Mahendra Fulchand Sundesha	Satwani Holdings LLP	4,282
							Narnarayan Nathmal Saraf	Satwani Holdings LLP	2,340
							Rosewood Investments	Satwani Holdings LLP	1,508,478
							From	To	No. of Shares
August 17, 2026	5,05,000	0.80%	2	988	Cash	Transfer	Anil Satwani	Motilal Oswal India Excellence Fund-Mid to Mega-Series-III	340,000
							Satwani Holdings LLP	Motilal Oswal India Excellence Fund-Mid to Mega-Series-III	165,000
							From	To	No. of Shares
August 19, 2026	65,57,619	10.45%	2	988	Cash	Transfer	India Business Excellence Fund- III	ValueQuest Founders Conviction LVF	1,771,255
							India Business Excellence Fund- III	ValueQuest Fastercap Fund II	253,035
							India Business Excellence Fund- III	WhiteOak Capital India Opportunities Fund	506,071
							India Business Excellence Fund- III	WhiteOak Capital Equity Fund	50,607
							India Business Excellence Fund- III	WhiteOak Capital Healthcare Opportunities Fund	50,607
							India Business Excellence Fund- III	Singularity Equity Fund I	454,395
							India Business Excellence Fund- III	Waterfield Flagship Fund II	151,820
							India Business Excellence Fund- III	Anshul Goel	50,605
							India Business Excellence Fund- III	Piyush Jalan Family Trust	50,605
							India Business Excellence Fund- III	Eterna Prima - Scheme II	101,215
							India Business Excellence Fund- III	1729 Growth Fund I	101,215
							India Business Excellence Fund- III	Jaya Chandrakant Gogri	101,215
							India Business Excellence Fund- III	Arvind Kapur	50,605
							India Business Excellence Fund- III	Landmark Capital Markets Private Limited	50,605
							India Business Excellence Fund- III	Aluka Kavitha	30,364
							Rosewood Investments	Think India Opportunities Master Fund LP	1,771,255
							Rosewood Investments	Dymon Asia Multi-Strategy Investment (Singapore) Pte. Limited	1,012,145

** As certified by M/s. A B M S & Associates, Chartered Accountants, by way of their certificate dated August 19, 2026.*

9. ***As a result of the transfer of the Sale Shares, disclosures in the sections "Basis for Offer Price - Weighted average cost of acquisition, Floor Price and Cap Price – d) Weighted average cost of acquisition ("WACA"), Floor Price and Cap Price" on page 161 of the RHP, stands modified as below:***

Based on the disclosures in (a) and (b) above, the WACA of the securities compared with the Floor Price and the Cap Price is set forth below:

Past transactions	Weighted average cost of acquisition per Equity Share (in ₹)	Comparison with Floor Price (₹ 938)	Comparison with Cap Price (₹ 988)
WACA of Primary Issuances as set out in (a) above	276.00	3.40 times	3.58 times
WACA of Secondary Transactions as set out in (b) above	834.23	1.12 times	1.18 times

As certified by M/s. A B M S & Associates, Chartered Accountants, by way of their certificate dated August 19, 2026.

The Red Herring Prospectus and all Offer related material shall be read in conjunction with this Addendum. The information in this Addendum supplements and updates the information in the Red Herring Prospectus. However, this Addendum does not purport to, nor does it, include all changes that have occurred from the date of filing of the Red Herring Prospectus and the date of this Addendum, except to the extent of the modifications included in this Addendum. Please note that the information included in the Red Herring Prospectus will be suitably updated, including to the extent updated by way of this Addendum, as may be applicable, in the Prospectus.

This Addendum shall be available on the website of SEBI at www.sebi.gov.in, the website of Stock Exchanges at www.nseindia.com and www.bseindia.com, the website of our Company at www.symbiotec.com and the websites of the Book Running Lead Managers, namely, JM Financial Limited at www.jmfl.com, Avendus Capital Private Limited at www.avendus.com, Motilal Oswal Investment Advisors Limited at www.motilaloswal.com, and Nomura Financial Advisory and Securities (India) Private Limited at www.nomuraholdings.com/company/group/asia/india/index.html. All capitalised terms used in this Addendum shall, unless the context otherwise requires, have the meanings ascribed to them in the Red Herring Prospectus.

BOOK RUNNING LEAD MANAGERS

JM Financial Limited
7th Floor, Cnergy Appasaheb Marathe Marg Prabhadevi,
Mumbai 400 025, Maharashtra, India
Telephone: +91 22 6630 3030
E-mail: symbiotec.ipo@jmfl.com
Investor Grievance email: grievance.ibd@jmfl.com
Website: www.jmfl.com
Contact Person: Prachee Dhuri
SEBI Registration No.: INM000010361

Avendus Capital Private Limited
Platina Building, 9th Floor, 901, Plot No C-59, Bandra Kurla Complex, Bandra (East), Mumbai - 400 051, Maharashtra, India
Telephone: +91 22 6648 0050
Email: symbiotec.ipo@avendus.com
Investor grievance email: investorgrievance@avendus.com
Website: www.avendus.com
Contact person: Sarthak Sawa / Ananya Chawla
SEBI Registration No: INM000011021

Motilal Oswal Investment Advisors Limited^^
Motilal Oswal Tower, Rahimtullah Sayani Road, Opposite Parel ST Depot, Prabhadevi, Mumbai – 400 025, Maharashtra, India
Telephone: +91 22 7193 4380
E-mail: spl.ipo@motilaloswal.com
Investor Grievance E-mail: moiaplredressal@motilaloswal.com
Website: www.motilaloswal.com
Contact Person: Kunal Thakkar/Vaibhav Shah
SEBI Registration No.: INM000011005

Nomura Financial Advisory and Securities (India) Private Limited
Ceejay House, Level 11, Plot F, Shiv Sagar Estate, Dr. Annie Besant Marg, Worli, Mumbai – 400 018, Maharashtra, India
Telephone: +91 22 4037 4037
E-mail: symbiotecipo@nomura.com
Investor Grievance E-mail: investorgrievances-in@nomura.com
Website: www.nomuraholdings.com/company/group/asia/india/index.html
Contact Person: Vishal Kanjani / Chirag Shah
SEBI Registration No.: INM000011419

REGISTRAR TO THE OFFER

MUFG Intime

MUFG Intime India Private Limited
(*Formerly Link Intime India Private Limited*)
C-101, Embassy 247, L.B.S. Marg, Vikhroli (West), Mumbai 400 083, Maharashtra, India
Telephone: +91 810 811 4949
Email: symbiotecpharmalab.ipo@in.mpms.mufg.com
Investor grievance email: symbiotecpharmalab.ipo@in.mpms.mufg.com
Website: www.in.mpms.mufg.com
Contact person: Shanti Gopalkrishnan
SEBI Registration No: INR000004058

COMPANY SECRETARY AND COMPLIANCE OFFICER

Salil Jain, 385/2, Pigdamber, Rau, Mhow, Indore – 453 331, Madhya Pradesh, India;
Email: secretarial@symbiotec.com

Bidders may contact the Company Secretary and Compliance Officer, the BRLMs or the Registrar to the Offer in case of any Pre-Offer or Post-Offer related problems, such as non-receipt of letters of Allotment, non-credit of Allotted Equity Shares in the respective beneficiary account, non-receipt of refund orders or non-receipt of funds by electronic mode. For all Offer-related queries and for redressal of complaints, investors may also write to the BRLMs.

^^In compliance with the proviso to regulation 21A(1) and explanation (iii) to regulation 21A(1) of the SEBI Merchant Bankers Regulations, and regulation 23(3) of the SEBI ICDR Regulations, Motilal Oswal Investment Advisors Limited will be involved only in marketing the Offer. Motilal Oswal Investment Advisors Limited has signed the due diligence certificate and has been disclosed as a BRLM for the Offer.

For **Symbiotec Pharmalab Limited**
On behalf of the Board of Directors
Sd/-
Salil Jain
Company Secretary and Compliance Officer

Place: Madhya Pradesh, India
Date: August 19, 2026

Symbiotec Pharmalab Limited is proposing, subject to applicable statutory and regulatory requirements, receipt of requisite approvals, market conditions and other considerations, to undertake an initial public offering of its Equity Shares and has filed the Red Herring Prospectus with the Registrar of Companies, Madhya Pradesh at Gwalior, SEBI and the Stock Exchanges on August 18, 2026. The Red Herring Prospectus shall be available on the websites of the Company i.e. www.symbiotec.com and SEBI, BSE and NSE at www.sebi.gov.in, www.bseindia.com and www.nseindia.com, respectively, and on the website of the Book Running Lead Managers i.e. JM Financial Limited at www.jmfl.com, Avendus Capital Private Limited at www.avendus.com, Motilal Oswal Investment Advisors Limited at www.motilaloswal.com and Nomura Financial Advisory and Securities (India) Private Limited at www.nomuraholdings.com/company/group/asia/india/index.html. Potential investors should note that investment in equity shares involves a high degree of risk and for details relating to such risk, see the section titled "*Risk Factors*" on page 28 of the RHP. Potential investors should not rely on the DRHP filed with SEBI for making any investment decision but should only rely on the information included in RHP filed by the Company with the RoC for making investment decisions.

This announcement does not constitute an invitation or offer of securities for sale in any jurisdiction.

The Equity Shares offered in the Offer have not been, and will not be, registered under the U.S. Securities Act of 1933, as amended ("**U.S. Securities Act**") or any other applicable law of the United States, and unless so registered may not be offered or sold within the United States, except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the U.S. Securities Act and applicable state securities laws. Accordingly, the Equity Shares are being offered and sold outside of the United States in "offshore transactions" as defined in and in reliance on Regulation S under the U.S. Securities Act and the applicable laws of the jurisdictions where such offers and sales are made.

Adfactors